RNTX - Rein Therapeutics Inc. Company Long-Term Liabilities

Graphic logo of Rein Therapeutics Inc. (RNTX)

Market fluctuations in Rein Therapeutics Inc (RNTX) share prices reflect debt dynamics, with the key metric recorded at 0.00. Rein Therapeutics Inc develops protective agents for the body during cancer therapy, gaining authority among physicians. Management is currently restructuring following the consolidation of assets to overcome a liquidity shortage. Strict regulatory standards and an extensive patent portfolio ensure a high barrier to entry.

Company Long-Term Debts: Rein Therapeutics Inc (RNTX) for 07/04/2022 - 11/01/2026

Rein Therapeutics, Inc. (RNTX) - metric breakdowns and financial figures

- market value and analyst target forecast:
Market Price aileronrx.com|RNTX - Analyst Consensus Forecast
- market capitalization statistics:
Market Valuation Rein Therapeutics|RNTX - Enterprise Value
- shareholders' equity book value data:
Net Assets per Share Rein Therapeutics|RNTX - Book Capitalization|Market Capitalization to Book Value Ratio aileronrx.com|RNTX - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Rein Therapeutics Inc|RNTX - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Aileron Therapeutics|RNTX - Company Total Debt|Debts to Book Capitalization Ratio Rein Therapeutics|RNTX - Company Long-Term Debts|Short-Term Debt Rein Therapeutics|Immediate Liquidity Ratio aileronrx.com
- company profitability and valuation multiples indicators:
RNTX - Net Income
Fundamental company valuation:aileronrx.com, RNTX
Manufactured products of Rein Therapeutics Inc

This indicator aggregates the total volume of liabilities with maturities exceeding one year, allowing for an assessment of long-term financial stability and capital expenditure strategy. By analyzing the history of long-term loans and borrowings of the corporation, one can understand how Rein Therapeutics Inc (RNTX) finances autonomous R&D and incentivizes its scientific staff while awaiting FDA approvals, which determines the business's fundamental ability to scale its drug portfolio.

Who Rein Therapeutics Inc competes with

vrtx.com (VRTX) - Long-Term Debt|Alnylam - Company Long-Term Debts|Insmed Inc. (INSM) - Company Long-Term Liabilities|UTHR: Company Long-Term Debts|BMRN - Long-Term Debt Volume|BBIO (BridgeBio Pharma, Inc.) - Company Long-Term Debts|Company Long-Term Debts BGM Group Corp|Company Long-Term Debt Cogent Biosciences, Inc. (COGT)|Company Long-Term Debt XERS (Xeris Biopharma Holdings, Inc.)|Company Long-Term Debts KROS (Keros Pharma)|Long-Term Debt Volume Arcturus Corp (ARCT)|ETON: Company Long-Term Liabilities|Long-Term Liabilities KMDA|FULC: Company Long-Term Debts|Long-Term Debt Abeona Therapeutics Inc. (ABEO)|MREO (Mereo BioPharma Group) - Company Long-Term Debts|Company Long-Term Indebtedness PLX (Protalix BioTherapeutics, Inc)|Company Long-Term Liabilities PLRX (Pliant Therapeutics)|APLT (Applied Therapeutics Inc.) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Gelteq GELS|AYTU (Aytu BioPharma Inc) - Long-Term Liabilities|Chemomab - Company Long-Term Debts|Company Long-Term Loans and Borrowings SRXH (SRx Health Solutions Inc.)|PLRZ: Company Long-Term Debts|Aeterna Zentaris Inc. (AEZS) - Company Long-Term Debts|Company Long-Term Debt Cyclo Therapeutics, Inc.|INZY: Company Long-Term Loans and Borrowings|Company Long-Term Debt Reneo Pharma (RPHM)|Company Long-Term Liabilities COSCIENS Bio CSCI